A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 283

Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
Times Cited: 100

List of shared articles

Times cited

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Emily N Risdon, Cindy H Chau, Douglas K Price, Oliver Sartor, William D Figg. Oncologist 2021

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Myrto Moutafi, Panagiota Economopoulou, David Rimm, Amanda Psyrri. Oral Oncol 2021

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.
Melissa M Pham, Natalie Y L Ngoi, Guang Peng, David S P Tan, Timothy A Yap. Trends Cancer 2021

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C Lee, Silviana Lee, Sumeet Nayak, John Krais, Pamela S VanderVere-Carozza, Katherine S Pawelczak, Jennifer Calvo,[...]. Mol Cell 2021

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021

A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
Bingnan Zhang, Kavya Ramkumar, Robert John Cardnell, Carl Michael Gay, C Allison Stewart, Wei-Lien Wang, Junya Fujimoto, Ignacio I Wistuba, Lauren Averett Byers. Br J Cancer 2021

Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP-a comparison of PARP imaging agents.
Sophie Stotz, Johannes Kinzler, Anne T Nies, Matthias Schwab, Andreas Maurer. Eur J Nucl Med Mol Imaging 2021

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.
Jeffrey W Johannes, Amber Balazs, Derek Barratt, Michal Bista, Matthew D Chuba, Sabina Cosulich, Susan E Critchlow, Sébastien L Degorce, Paolo Di Fruscia, Scott D Edmondson,[...]. J Med Chem 2021

Targeting DNA repair in cancer: current state and novel approaches.
Apostolos Klinakis, Dimitris Karagiannis, Theodoros Rampias. Cell Mol Life Sci 2020

53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Jianfang Ning, Hiroaki Wakimoto. Trends Cancer 2020